Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

Sponsor
Haukeland University Hospital
Study ID
NCT00139360
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To determine the efficacy as measured by objective tumor response of first-line treatment of metastatic melanoma with bevacizumab monotherapy

Key Dates

First listed
Aug 31, 2005
Start date
May 31, 2005
Status verified
Aug 2015
Primary completion
Jul 31, 2011
Completion
Jul 31, 2011

Study Design

Enrollment
35 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Active drug

Primary Outcome Measure

Clinical Response rates [ Time Frame: Evaluated by CT scans every 12 weeks, later every 6 monts. Up to 10 years. ]

Related Studies